Scott Barnett

Scott Barnett serves as an Assistant Professor in the Department of Biochemistry & Molecular Biology at the University of Nevada, Reno, focusing on molecular pathways in uterine physiology to combat preterm labor through novel drug development.

His academic credentials include:

• B.S. from University of Nevada, Reno (2011)
• Ph.D. from University of Nevada, Reno School of Medicine (2017)

Dr. Barnett's research centers on reproductive pharmacology, specifically developing placenta-impermeable tocolytics targeting myometrial relaxation mechanisms. His work integrates molecular biology, smooth muscle physiology, and translational drug discovery to address the critical unmet need for FDA-approved preterm labor treatments. Key approaches include modulation of β3 adrenergic receptors, connexin 43 dynamics, and mechanosensitive ion channels like Piezo1 and TREK-1.

Analysis of his publication record reveals consistent innovation in dual-pathway targeting strategies, with recent emphasis on small-molecule modulators of endoplasmic reticulum trafficking (Cx43/OXTR) and synergistic ion channel activation. His nephrology-related work demonstrates parallel expertise in multi-target therapeutics for diabetic complications.

Dr. Barnett holds a provisional patent for a preterm labor treatment, reflecting his translational impact.

While no formal advisees are documented, his program actively develops novel therapeutics and previously explored dual-purpose nephrology drugs. Research is supported by patent-protected innovation and likely grant funding for molecular obstetrics.

His laboratory focuses on human myometrial tissue studies, combining molecular signaling analysis with functional contractility assays to bridge basic science and clinical obstetrics.